Preview

Rational Pharmacotherapy in Cardiology

Advanced search

MODERN PHARMACOTHERAPY OF THE STABLE ANGINA: POSSIBILITIES AND PROSPECTS OF NICORANDIL IMPLEMENTATION

https://doi.org/10.20996/1819-6446-2010-6-4-455-460

Full Text:

Abstract

Aim. To evaluate antianginal efficacy and safety of nicorandil for angina attack prevention and relief in patients with ischemic heart disease (IHD) and symptoms of stable angina class 2-3.

Material and methods. 30 patients with stable angina class 2-3 (17 men, 13 women; aged 58.6±5.8 y.o.) were included into the study. All patients received amlodipine 10 mg QD within 2 weeks. For angina attack relief patients used nicorandil 10-20 mg and in case of its inefficacy — nitroglycerin. In 2 weeks all patients were randomized in 2 groups. Patients of the 1st group (n=15) received nicorandil 20 mg TID, patients of the 2nd group (n=15) — amlodipine 10 mg QD. The study duration was 3 months. The efficiency evaluation was based on the analysis of hemodynamic indicators (heart rate, blood pressure), bioelectric heart activity (electrocardiogram), velocity exercise tolerance test, ambulatory blood pressure monitoring indicators. The pain severity was defined with Borg's scale, and the quality of life — with General Health Questionnaire (GHQ-28). Therapy safety was evaluated in according to laboratory tests results.

Results. Frequency of angina attacks reduced by 60% (р<0.05) and 47% (р<0.05) in 12 weeks of nicorandil and amlodipine therapy, respectively. Duration of angina decreased by 38% and 37% (р<0.05) in 12 weeks of nicorandil and amlodipine therapy, respectively. Eexercise duration before angina attack onset increased by 56% (р<0.05) in 1 month of nicorandil therapy. A number of myocardial ischemia episodes reduced by 64% (р<0.05) and 54% (р<0.05) due to nicorandil and amlodipine therapy, respectively. General GHQ-28 score decreased by 54% (р<0.05) and 44% (р<0.05) in patients of the 1st and the 2nd groups, respectively. Tolerability of nicorandil was good in 13 (86.7%) and satisfactory in 2 (13.3%) patients.

Conclusion. Nicorandil can be prescribed both for the prevention and for relief of angina attacks in IHD patients.

About the Authors

Z. M. Sizova
I.M. Setchenov First Moscow State Medical University
Russian Federation
Trubetskaya ul. 8-2, Moscow, 119991


E. V. Shikh
I.M. Setchenov First Moscow State Medical University
Russian Federation
Trubetskaya ul. 8-2, Moscow, 119991


V. L. Zakharova
I.M. Setchenov First Moscow State Medical University
Russian Federation
Trubetskaya ul. 8-2, Moscow, 119991


E. V. Smirnova
Moscow Cardiologic dispensary N2
Russian Federation
Fruktovaya ul. 12, Moscow, 117556


References

1. Ольбинская Л.И., Сизова Ж.М. Фармакотерапия хронической сердечной недостаточности. М.: Русский врач; 2002.

2. Чазов Е.И., Беленков Ю.Н., редакторы. Рациональная фармакотерапия сердечно-сосудистых заболеваний: Руководство для практикующих врачей. М.: Литерра; 2005.

3. ОльбинскаяЛ.И., Морозова Т.Е., Сизова Ж.М. и др. Фармакотерапия хронических сердечно-сосудистых заболеваний: Руководство для врачей. М.: Медицина; 2006.

4. Шевченко О.П., Мишнев О.А., Шевченко А.О. и др. Ишемическая болезнь сердца. М.: Реафарм; 2005.

5. Fox K., Garcia M.A., Ardissino D. et al. Guidelines on the management of stable angina pectoris: executive summary: The Task Force on the Management of StableAngina Pectoris ofthe European Society of Cardiology. Eur Heart J 2006;27(11):1341-81.

6. IONA Study Grup. Effect of nicorandil on coronary events in patients with stable angina: the Impact Of Nicorandil in Angina (IONA): randomized trial. Lancet 2002;359(9314):1269–75.

7. Kinoshita M., Sakai K. Pharmacology and therapeutic effects of nicorandil. Cardiovasc Drugs Ther 1990;4(4):1075-88.

8. Meany T.B., Richardson P., Camm A.J. et al. Exercise capacity after single and twice-daily doses of nicorandil in chronic stable angina pectoris. Am J Cardiol 1989;63(21):66J-70J.

9. Taira N. Nicorandil as a hybrid between nitrates and potassium channel activators. Am J Cardiol 1989;63(21):18J-24J.

10. Roland E. Safety profile of an anti-anginal agent with potassium channel opening activity: an overview. Eur HeartJ 1993;14 Suppl B:48-52.

11. Hochachka P.W., Buck L.T., Doll C.J., Land S.C. Unifying theory of hypoxia tolerance: molecular/metabolic defense and rescue mechanisms for surviving oxygen lack. Proc Natl Acad Sci U S A 1996;93(18): 9493-8.

12. Lange R., Ingwall J.S., Hale S.L. et al. Effects of recurrent ischemia on myocardial high energy phosphate content in canine hearts. Basic Res Cardiol 1984;79(4):469-78.

13. Murry C.E., Richard V.J., Reimer K.A., Jennings R.B. Ischemic preconditioning slows energy metabolism and delays ultrastructural damage during a sustained ischemic episode. Circ Res 1990;66(4):913-31.

14. Rezkalla S.H., Kloner R.A. Preconditioning in humans. Heart Fail Rev 2007;12(3-4):201-6.

15. Wu Z.K., Iivainen T., Pehkonen E. et al. Ischemic preconditioning suppresses ventriculartachyarrhythmias after myocardial revascularization. Circulation 2002;106(24):3091-6.

16. Airaksinen K.E., Huikuri H.V. Antiarrhythmic effect of repeated coronary occlusion during balloon angioplasty. J Am Coll Cardiol 1997;29(5):1035-8.

17. Gheeraert P.J., Henriques J.P., De Buyzere M.L. et al. Preinfarction angina protects against out-of-hospital ventricular fibrillation in patients with acute occlusion of the left coronary artery. J Am Coll Cardiol 2001;38(5):1369-74.

18. Cokkinos D.V., Pantos C. Myocardial protection in man – from rese￾arch concept to clinical practice.Heart Fail Rev 2007;12(3-4):345-62.

19. Kitakaze M., Asakura M., Kim J. et al. Human atrial natriuretic peptide and nicorandil as adjuncts to reperfusion treatment for acute myocardial infarction (J-WIND): two randomised trials. Lancet 2007;370(9597):1483-93.

20. Matsuo H., Watanabe S., Segawa T. et al. Evidence of pharmacologic preconditioning during PTCA by intravenous pretreatment with ATPsensitive K+ channel opener nicorandil. Eur Heart J 2003;24(14): 1296-303.

21. Iliodromitis E.K., Cokkinos P., Zoga A. et al. Oral nicorandil recaptures the waned protection from preconditioning in vivo. Br J Pharmacol 2003;138(6):1101-6.

22. Lee T.M., Su S.F., Chou T.F. et al. Loss of preconditioning by attenuated activation of myocardial ATP-sensitive potassium channels in elderly patients undergoing coronary angioplasty. Circulation 2002;105(3): 334-40.

23. Kloner R.A., Shook T., Przyklenk K. et al. Previous angina alters in-hospital outcome in TIMI 4.Aclinical correlate to preconditioning? Circulation 1995;91(1):37-45.

24. Haghfelt T.H. Ivabradine — a medical alternative for patients with chronic stable angina pectoris. Ugeskr Laeger 2006;168(46):3991-3.


For citation:


Sizova Z.M., Shikh E.V., Zakharova V.L., Smirnova E.V. MODERN PHARMACOTHERAPY OF THE STABLE ANGINA: POSSIBILITIES AND PROSPECTS OF NICORANDIL IMPLEMENTATION. Rational Pharmacotherapy in Cardiology. 2010;6(4):455-460. (In Russ.) https://doi.org/10.20996/1819-6446-2010-6-4-455-460

Views: 305


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)